Phase II open-label global study to evaluate the effect of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive Low Grade Glioma (LGG) or relapsed or refractory High Grade Glioma (HGG)

  • STATUS
    Recruiting
Send
Updated on 19 February 2024

Summary

The purpose of this study is to investigate the activity of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive low grade glioma or relapsed or refractory high grade glioma.

Description

The purpose of this clinical research study is to find out if the drugs dabrafenib and trametinib are safe and beneficial in people with BRAF mutation positive LGG or relapsed or refractory BRAF mutation positive HGG.
Participants will not be paid for their participation.

FAQ

Participants will not be paid for their participation.

Details
Condition Zanthiastrocytoma,Rosette-forming Glioneurona Tumor,Glioma,Astrocytoma,Iponeurocytoma,Gangliocytoma,High Grade Glioma,Glioblastoma,BRAF mutation,Papillary Glioneuronal Tumor,Oligodenroglioma,Low Grade Glioma,Neurocytoma
Age 1years - 17years
Clinical Study IdentifierTX8998
Last Modified on19 February 2024

Eligibility

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact label
Race
Ethnicity
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.